Analysis of potential categories and influencing factors of prostate cancer patients' participation in shared decision making / 中国实用护理杂志

Objective:To explore the potential categories of prostate cancer patients′ participation in shared decision making, and analyze the characteristics and influencing factors of different categories of prostate cancer patients′ participation, so as to provide theoretical support for improving prostate cancer patients′ participation in shared decision making.Methods:This was a cross-sectional study. A total of 292 patients with a first diagnosis of prostate cancer without metastasis from three tertiary grade A hospitals in Zhengzhou were selected from October 2019 to October 2020 (Henan Provincial People′s Hospital, the First Affiliated Hospital of Zhengzhou University, the First Affiliated Hospital of Henan University of Chinese Medicine). The general data questionnaire, the Decisional Engagement Scale, Perceived Social Support Scale and Disease Uncertainty Scale were used. Latent class analysis was used to classify prostate cancer patients according to shared decision making participation, and Logistic regression was used to analyze the influencing factors of the potential category.Results:The total scores of the Decisional Engagement Scale, Perceived Social Support Scale and Disease Uncertainty Scale in prostate cancer patients were (67.28 ± 20.77), (62.34 ± 15.39), (95.06 ± 8.05) points, respectively. The shared decision making participation of prostate cancer patients was divided into three potential categories: high participation group 76.4%(223/292), moderate participation group 12.7%(37/292), and low participation group 11.0%(32/292). Taking high participation group as reference, age( OR=1.088, 95% CI 1.161-1.231, P<0.05) and illness uncertainty( OR=1.480, 95% CI 1.414-1.919, P<0.05) were the risk factors for the low participation group; perceived social support was the protective factor ( OR=0.857, 95% CI 0.775-0.946, P<0.05). Illness uncertainty was the risk factor( OR=1.525, 95% CI 1.316-1.767, P<0.05), and perceived social support was the protective factor ( OR=0.829, 95% CI 0.838-0.949, P<0.05) for the moderate participation group. Conclusions:There were obvious classification characteristics of shared decision making participation for prostate cancer patients. Age, perceived social support and illness uncertainty were the influencing factors of it. Interventions should be taken according to the characteristics of each category, to improve the level of shared decision making of prostate cancer patients.

Effects of miR-1249-5p on proliferation, metastasis and cell cycle of prostate cancer PC-3 cell / 国际外科学杂志

Objective:To explore the effect of miR-1249-5p on the proliferation, metastasis and cell cycle of PC-3 cell in prostate cancer.Methods:The relationship between the expression level of miR-1249-5p and the overall survival of prostate cancer patients was analyzed using OncoMir Cancer Database (OMCD). The human prostate cancer cell line PC-3 was divided into two groups: miR-1249-5p group and negative control group. Mediated by Lipofectamine 2000, miR-1249-5p mimics liposome complex or negative miRNA liposome complex were transfected into PC-3 cell at logarithmic growth stage. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-1249-5p in PC-3 cell of two groups. Colony formation assay was used to detect the changes of the proliferation ability of PC-3 cell in the two groups. Transwell experiment was used to detect the changes of PC-3 cell invasion in the two groups, and the cell cycle changes of the two groups of PC-3 were detected by flow cytometry. The miRNA prediction software miRGator was used to predict the target gene of miR-1249-5p. RT-qPCR and Western blotting were used to detect the target gene expression of miR-1249-5p. Measurement data were expressed as mean±standard deviation ( ± s), and t-test was used for comparison between two groups. Results:Compared with prostate cancer patients with low miR-1249-5p expression, prostate cancer patients with higher miR-1249-5p expression had longer overall survival, and the difference was statistically significant ( P<0.01). The expression level of miR-1249-5p in the miR-1249-5p group (10.74±1.19) was significantly higher than that of the negative control group (1.56±0.27), the difference was statistically significant ( P<0.01). The number of colonies formed in the miR-1249-5p group (35.86±6.94) was significantly less than that in the negative control group (88.94±11.66), and the difference was statistically significant ( P<0.01). The number of transmembrane cells [(25.01±6.83)/high power field of view] in the miR-1249-5p group was significantly less than that of the negative control group [(82.76±8.35)/high power field of view], and the difference was statistically significant ( P<0.01). The proportion of cells in the G 0-G 1 phase in the miR-1249-5p group [(50.79±6.61)%] was significantly higher than that in the negative control group [(27.09±2.30)%], the difference was statistically significant ( P<0.01), and PC-3 cell were inhibited in the G 0-G 1 phase. Neural precursor cell expressed developmentally down-regulated 9 ( NEDD9) may be the target gene of miR-1249-5p. Compared with the negative control group, the NEDD9 gene expression in the miR-1249-5p group was significantly lower than that of the negative control group, the difference was statistically significant ( P<0.01). Conclusion:miR-1249-5p can inhibit the proliferation, metastasis and cell cycle of PC-3 cell in prostate cancer, which may be achieved by negatively regulating the expression of proto-oncogene NEDD9.

Risk factors and misdiagnosis of intraductal carcinoma of prostate (IDC-P)in patients with metastatic prostate cancer / 中华泌尿外科杂志

Objective:To investigate the risk factors and missed diagnosis of intraductal carcinoma of prostate (IDC-P) in patients with metastatic prostate cancer.Methods:The preoperative PSA, prostate MRI, bone scans and lung CT of all patients who underwent prostate biopsy in Department of Urology, Xiangya Hospital, Central South University from January 2018 to July 2020 were reviewed. A total of 261 patients with high suspicion of metastatic prostate cancer were screened for inclusion. Two full-time senior pathologists of urogenital tumors in Xiangya Hospital independently reviewed their pathological sections and detected IDC-P according to the 2016 WHO tumor classification. Diagnostic criteria are defined as malignant epithelial cells filling large acini and prostatic ducts, with preservation of basal cells and solid or dense cribriform pattern/loose cribriform or micropapillary pattern with either marked nuclear atypia or non-focal comedonecrosis.Results:The detection rate of IDC-P was 29.12%(76/261), while the actual reporting rate was only 9.96%(26/261). The results of subgroup analysis including age, PSA level, Gleason score as well as different metastatic sites showed that detection rate of IDC-P was 33.69% in the PSA≥50 ng/ml subgroup, much higher than 17.57% in the PSA <50 ng/ml subgroup ( P=0.0039); And it was 32.33% in the Gleason score ≥ 8 subgroup, much higher than 3.45% in the Gleason score < 8 subgroup ( P<0.01). It was not significantly different in different age subgroups as well as different metastatic site subgroups. These data suggest that PSA ≥ 50 ng/ml as well as Gleason score ≥ 8 may be risk factors of IDC-P.157 samples were stained by immunohistochemistry. The detection rates of IDC-P were 84.21% (16/19) in P63 (+ ) samples, 36.00% (9/25) in ERG (+ ) samples. There were 3 samples with both P63 (+ ) and ERG (+ ), all of which had IDC-P. Conclusions:There is misdiagnosis of IDC-P on prostate needle biopsy in patients with metastatic prostate cancer currently. PSA ≥ 50 ng/ml and Gleason score ≥ 8 are risk factors of IDC-P. Thus, attention should be paid to the possibility of IDC-P in such patients. When the diagnosis is difficult, immunohistochemical staining for ERG and P63 is helpful in IDC-P determination.

A deep learning method for generating pseudo-CT by cone beam CT in radiotherapy / 中华放射肿瘤学杂志

Objective:To investigate the pseudo-CT generation from cone beam CT (CBCT) by a deep learning method for the clinical need of adaptive radiotherapy.Methods:CBCT data from 74 prostate cancer patients collected by Varian On-Board Imager and their simulated positioning CT images were used for this study. The deformable registration was implemented by MIM software. And the data were randomly divided into the training set ( n=59) and test set ( n=15). U-net, Pix2PixGAN and CycleGAN were employed to learn the mapping from CBCT to simulated positioning CT. The evaluation indexes included mean absolute error (MAE), structural similarity index (SSIM) and peak signal to noise ratio (PSNR), with the deformed CT chosen as the reference. In addition, the quality of image was analyzed separately, including soft tissue resolution, image noise and artifacts, etc. Results:The MAE of images generated by U-net, Pix2PixGAN and CycleGAN were (29.4±16.1) HU, (37.1±14.4) HU and (34.3±17.3) HU, respectively. In terms of image quality, the images generated by U-net and Pix2PixGAN had excessive blur, resulting in image distortion; while the images generated by CycleGAN retained the CBCT image structure and improved the image quality.Conclusion:CycleGAN is able to effectively improve the quality of CBCT images, and has potential to be used in adaptive radiotherapy.

Câncer de próstata em trabalhadores rurais expostos a agrotóxicos: revisão de escopo / Prostate cancer in rural workers exposed to agrochemicals: scope review

Desde o início dos anos 2000 é crescente o número de estudos que avaliam a exposição a agrotóxicos e suas consequências para a saúde do trabalhador. Contudo, não há sistematização da produção relacionada ao câncer de próstata em trabalhadores rurais. Assim, objetivou-se mapear a literatura que trata da associação entre a exposição aos agrotóxicos e a ocorrência de câncer de próstata em trabalhadores rurais. Foi realizada uma revisão de escopo nas bases de dados Web of Science (WoS), Scopus, Cumulative Index to Nursing and Allied Health Literature (CINHAL) e Biblioteca Virtual em Saúde (BVS), empregando os descritores "Agrochemicals", "Farmers" e "Prostatic Neoplasms". Dezenove artigos fizeram parte desta revisão. Em dezessete, verificou-se associações entre a ocorrência de câncer de próstata em trabalhadores rurais e a exposição a agrotóxicos. Os fatores de risco relacionados foram: histórico familiar, tabagismo, raça/cor, idade avançada, alterações genéticas, toneladas de soja produzidas e o uso de agrotóxicos específicos. A literatura aponta a existência de consistência e plausibilidade biológica para a ocorrência de câncer de próstata em indivíduos expostos a agrotóxicos que exercem atividades agrícolas.

Since the early 2000s there has been an increasing number of studies evaluating pesticide exposure and its consequences for worker health. However, they are not systematized in relation to prostate cancer in rural workers. We aimed to map the literature dealing with the association between exposure to pesticides and the occurrence of prostate cancer in rural workers. A scoping review was conducted in the Web of Science (WoS), Scopus, Cumulative Index to Nursing and Allied Health Abstract Literature (CINHAL) and Virtual Health Library (VHL) databases. The descriptors "Agrochemicals", "Farmers" and "Prostatic Neoplasms" were employed. Nineteen articles were part of this review. In seventeen articles, associations were found between the occurrence of prostate cancer in rural workers and exposure to agrochemicals. The related risk factors were: family history, smoking, race/color, advanced age, genetic alterations, tons of soybeans produced, and the use of specific pesticides. The literature points to the existence of consistency and biological plausibility for the occurrence of prostate cancer in individuals exposed to pesticides who perform agricultural activities.

Effects of propofol on malignant biological behaviors of prostate cancer DU145 cells and its mechanism / 国际肿瘤学杂志

Objective:To investigate the effects of propofol on malignant biological behaviors of prostate cancer DU145 cells and its possible mechanism.Methods:Control group, 5-fluorouracil group (200 ng/ml) , low-dose propofol group (100 ng/ml) and high-dose propofol group (400 ng/ml) were set up. CCK-8 kit was used to measure the level of cell proliferation, Transwell method was used to measure the abilities of cell invasion and migration, flow cytometry was used to measure the level of apoptosis, and qRT-PCR and Western blotting were used to measure hepatocyte growth factor (HGF) and c-Met mRNA and protein levels.Results:The survival rates of the control group, 5-fluorouracil group, low-dose propofol group and high-dose propofol group were (83.32±3.02) %, (36.29±3.54) %, (62.01±4.69) % and (40.20±5.48) % ( F=8.65, P=0.006) ; the apoptosis rates were (2.36±0.41) %, (12.47±0.40) %, (6.28±0.39) % and (10.24±0.37) % ( F=26.73, P=0.001) . Further pairwise comparison showed that there were statistically significant differences (all P<0.05) . The numbers of penetrating membranes of the four groups were 617.45±29.86, 125.27±24.38, 407.02±32.27 and 230.74±31.59 ( F=18.33, P=0.002) ; the migration distances were (603.85±27.74) μm, (121.69±25.85) μm, (395.59±28.37) μm and (233.52±30.42) μm ( F=27.02, P=0.001) . Further pairwise comparison showed that there were statistically significant differences (all P<0.05) . HGF mRNA expression levels of the four groups were 6.26±0.39, 1.94±0.35, 4.15±0.37 and 2.90±0.33 ( F=25.31, P=0.001) ; c-Met mRNA expression levels were 5.85±0.30, 2.04±0.32, 3.89±0.31 and 2.94±0.32 ( F=12.12, P=0.003) ; HGF protein expression levels were 1.43±0.04, 0.34±0.08, 0.86±0.06 and 0.63±0.09 ( F=17.02, P=0.001) ; c-Met protein expression levels were 1.63±0.14, 0.39±0.15, 0.93±0.11 and 0.64±0.17 ( F=19.89, P=0.001) . Further pairwise comparison showed that there were statistically significant differences (all P<0.05) . Conclusion:Propofol has obvious inhibitory effects on the malignant biological behaviors of prostate cancer DU145 cells, and the inhibitory effect of high-dose propofol is more obvious. The mechanism may be related to the inhibition of HGF and c-Met mRNA and protein expressions of DU145 cells by propofol, which inhibits the activation of HGF/c-Met pathway.

Óbito neonatal em maternidade pública de referência: fatores associados / Transition of elderly men with prostate cancer: analysis of facilitating and difficulty conditions / Transición de ancianos con cáncer de próstata: análisis de condiciones facilitadoras y de dificultad

Objetivo: compreender a experiência de transição de homens idosos na experiência com o câncer de próstata. Método: estudo descritivo de abordagem qualitativa realizado em quatro serviços da rede de atenção à saúde de uma cidade da Bahia, Brasil. Os dados foram coletados por meio de entrevista semiestruturada com oitenta homens idosos, as quais foram organizados e analisados com base na Técnica do Discurso do Sujeito Coletivo e interpretados à luz da Teoria das Transições. Resultados: são facilitadores a influência de familiares, amigos, outros homens, enfermeiros e demais profissionais; e dificultadores a escassez do conhecimento e recursos financeiros do indivíduo, barreiras geográficas, limitações relacionadas à estrutura e burocracia dos serviços. Considerações finais: ao construir sentidos para o câncer de próstata e admitir a vulnerabilidade, os homens confrontam suas crenças, alcançam a consciencialização que permite superar limitações e assumir o protagonismo do cuidado de si na transição da saúde/doença.

Objective: to understand the transition experience of elderly men with prostate cancer. Method: descriptive study with a qualitative approach carried out in four services of the health care network in a city in Bahia, Brazil. Data were collected through semi-structured interviews with eighty elderly men, which were organized and analyzed based on the Collective Subject Discourse Technique and interpreted in light of the Theory of Transitions. Results: the influence of family members, friends, other men, nurses and other professionals are facilitators; and complicating factors are the scarcity of knowledge and financial resources of the individual, geographic barriers, limitations related to the structure and bureaucracy of services. Final considerations: when constructing meanings for prostate cancer and admitting vulnerability, men confront their beliefs, reach the awareness that allows them to overcome limitations and assume the leading role of self-care in the health/disease transition.

Objetivo: comprender la experiencia de transición de ancianos con cáncer de próstata. Método: estudio descriptivo con abordaje cualitativo realizado en cuatro servicios de la red de atención a la salud de un municipio de Bahía, Brasil. Los datos fueron recolectados a través de entrevistas semiestructuradas con ochenta ancianos, que fueron organizadas y analizadas a partir de la Técnica del Discurso del Sujeto Colectivo e interpretadas a la luz de la Teoría de las Transiciones. Resultados: la influencia de familiares, amigos, otros hombres, enfermeras y otros profesionales son facilitadores; y los factores que complican son la escasez de conocimientos y recursos financieros del individuo, las barreras geográficas, las limitaciones relacionadas con la estructura y la burocracia de los servicios. Consideraciones finales: al construir significados para el cáncer de próstata y admitir la vulnerabilidad, los hombres confrontan sus creencias, alcanzan la conciencia que les permite superar las limitaciones y asumir el papel protagónico del autocuidado en la transición salud/enfermedad.

Vigilância ativa do câncer de próstata - um conceito em evolução / Active surveillance of prostate cancer - an ongoing concept

A vigilância ativa é a solução encontrada pela urologia para a condução de tumores prostáticos com características de pouca agressividade. Desenvolvida especialmente após as polêmicas que envolveram a validade do rastreamento, essa abordagem vem sendo consolidada como a melhor maneira de se evitar o tratamento desnecessário do câncer de próstata e precisa ser compreendida por todos os médicos que lidam com a saúde do homem.

Active surveillance is the solution found by urology to deal with low-aggressivity prostate tumours. Having been developed following controversies over screening strategies, this has been considered the best approach to avoid unnecessary treatment of prostate cancer and such a concept needs to be well understood by every medical doctor who deals with men's health.

Prostate cancer mortality in Brazil 1990-2019: geographical distribution and trends

Abstract INTRODUCTION: To analyze the trend of prostate cancer mortality in the Brazilian population of 40 years of age and above. METHODS: Time series ecological study of the mortality rates due to prostate cancer in men of 40 years of age and above, using data from the Global Burden of Disease 2019 (GBD). Age-standardized mortality rates were calculated, as well as the age-standardized rates by the GBD for the global population, per 100,000 inhabitants, for Brazil and its States, from 1990 to 2019. The annual average percent change (AAPC) was calculated to identify the mortality trends in Brazil, through linear regression using the Joinpoint Regression Program. RESULTS: The standardized rates of prostate cancer mortality in Brazil were 76.89 in 1990 and 74.96 deaths for every 100 thousand men ≥ 40 years of age in 2019, with a stability trend. By age group, it was observed a decreasing trend up to 79 years of age, and an increasing trend as of 80 years of age. The state of Bahia showed the highest increase in mortality in the period (1.2%/year), followed by Maranhão and Pernambuco (1.0 and 0.9%/year). A decrease of prostate cancer mortality was found in the Federal District, Goiás, Minas Gerais, Rio de Janeiro, Rio Grande do Sul, Roraima, Santa Catarina, São Paulo, and Sergipe. CONCLUSIONS: In Brazil, the standardized mortality rates show a trend toward stability from 1990 to 2019 and no pattern was observed for the trends according to the Brazilian States.

China guideline for the screening and early detection of prostate cancer (2022, Beijing) / 中华肿瘤杂志

Prostate cancer (PC) is one of the malignant tumors of the genitourinary system that occurs more often in elderly men. Screening, early diagnosis, and treatment of the PC high risk population are essential to improve the cure rate of PC. The development of the guideline for PC screening and early detection in line with epidemic characteristics of PC in China will greatly promote the homogeneity and quality of PC screening. This guideline was commissioned by the Bureau of Disease Control and Prevention of the National Health Commission. The National Cancer Center of China initiated and convened a working group comprising multidisciplinary experts. This guideline strictly followed the World Health Organization Handbook for Guideline Development and combined the most up-to-date evidence of PC screening, China's national conditions, and practical experience in cancer screening. A total of fifteen detailed evidence-based recommendations were provided with respect to the screening population, technology, procedure management, and quality control in the process of PC screening. This guideline aimed to standardize the practice of PC screening and improve the effectiveness and efficiency of PC prevention and control in China.

Application of image fusion biopsy based on PSMA PET in prostate cancer / 中华泌尿外科杂志

Prostate biopsy is the gold standard for diagnosis of prostate cancer. Positron emission tomography (PET) of prostate-specific membrane antigen is a new imaging technology, which has high clinical value in the detection of Clinically Significant Prostate Cancer. It also has high recognition ability for local recurrence and lymph node metastasis. Targeted prostate biopsy guided by PSMA PET can improve the detection rate of clinically significant prostate cancer, help guide the selection of prostate cancer bone biopsy lesions, plan the needle path, and improve the success rate of bone biopsy in patients with mCRPC. However, prospective randomized controlled studies are still needed to explore the feasibility of PSMA PET in targeted biopsy of prostate cancer.

Autopsy studies of latent prostate cancer / 中华泌尿外科杂志

Latent prostate cancer is defined as prostate cancer that was undiagnosed during life and then detected through autopsy. As a complement to clinical data of diagnosed prostate cancer, autopsy studies provide us with epidemiological and pathological characteristics of latent prostate cancer and facilitate our understanding of this disease. Though differences in time, population, methods, and reporting of results across studies exist, we managed to integrate findings of global autopsy studies on latent prostate cancer, analyze the effect of methodology on the results and propose deficiencies as well as directions for further research.

Efficacy of the biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer / 中华泌尿外科杂志

Objective:To investigate the efficacy of the biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy on prostate cancer (PCa) detection in biopsy-na?ve patients.Methods:The clinical data of 121 biopsy-na?ve patients who underwent transperineal prostate biopsy in West China Hospital of Sichuan University from July 2018 to January 2020 were retrospectively analyzed. The average age was (64.7±9.1) years old. Pre-biopsy prostate-specific antigen (PSA) was (12.4±7.5)ng/ml, f/t PSA was 0.13±0.05. Prostate volume was (43.1±26.1) ml and PASD was (0.35±0.27) ng/ml 2. The prostate-imaging and data system (PI-RADS) score of MRI before biopsy was reported to be 3 for 29 patients (24.0%), 4 for 54 patients (44.6%) and 5 for 38 patients (31.8%). All 121 patients underwent 12-core systematic biopsy combined with a 3-core or 5-core MRI-targeted biopsy, of which 61 patients underwent 3-core targeted biopsy and 60 underwent 5-core targeted biopsy. There was no significant difference in the pre-biopsy clinical data between the two groups ( P>0.05). A 6-core systematic biopsy was redefined as the results of 6 cores among the 12-core systematic biopsy. We compared the detection rates among the single 12-core systematic biopsy, 6-core systematic biopsy, MRI-targeted biopsy (3-core or 5-core), and different systematic biopsy combing with targeted biopsy for any PCa and clinically significant PCa, and we also analyzed the cumulative cancer detection rates for MRI-targeted biopsy of different cores. Results:Of the 121 patients in this study, the biopsy results were negative for 43 patients (35.5%) and positive for 78 (64.5%). The detection rate of clinically significant PCa was 55.4% (67/121). The detection rate of the 6-core systematic biopsy combined with MRI-targeted biopsy was 62.0% (75/121) for PCa and 55.4% (67/121) for clinically significant PCa, which was of no difference compared with that for the 12-core systematic biopsy combined with MRI-targeted biopsy ( P>0.05), but the 6-core systematic biopsy combined with MRI-targeted biopsy avoided the overdiagnosis of 3 patients with Gleason score 3+ 3. The detection rate of PCa for MRI-targeted biopsy was 57.9% (70/121), including 42.1% (51/121) for the first core, 55.4% (67/121) for the first two cores, and 57.9% (70/121) for the first three cores. Compared with the single-core targeted biopsy for suspicious lesions, the first 2-core targeted biopsy ( OR=1.7, 95% CI 1.0-2.8) and 3-core targeted biopsy ( OR=1.9, 95% CI 1.1-3.1) can significantly increase the detection rate of PCa, while the fourth or fifth core of targeted biopsy can not increase the detection rate additionally (60%, 36/60). Conclusion:For patients with suspected PCa, the prostate biopsy strategy combing 6-core systematic and 3-core MRI-targeted biopsy performs no inferior than the current 12-core systematic biopsy combined with MRI-targeted biopsy.

Physcion regulates the cell cycle and proliferation of prostate cancer through miR-380-3p / 国际外科学杂志

Objective:To investigate the mechanism of physcion affecting the cell cycle and proliferation of prostate cancer DU145 cell line by regulating the expression of miR-380-3p.Methods:Prostate cancer DU145 cells were treated with 50 μg/mL physcion as physcion group, and normal cultured DU145 cells without any treatment were used as control group. Flow cytometry was used to detect DU145 cell cycle changes. MTT proliferation test was used to detect the proliferation of DU145 cells. quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of miR-380-3p in DU145 cells. The bioinformatics software RNAhybrid was used to predict the target genes of miR-380-3p. qRT-PCR and Western blotting methods were used to detect the expression of miR-380-3p target gene. Measurement data were expressed as mean ± standard deviation ( ± s), t-test was used for comparison between two groups. Results:Compared with the control group, DU145 cells in the physcion group were blocked in the G 0/G 1 phase ( P<0.01), and the proliferation ability of DU145 cells was significantly inhibited ( P<0.05). The expression of miR-380-3p in DU145 cells in the control group and physcion group was 8.36 ± 1.42 and 1.08 ± 0.39, respectively. Physcion could promote the expression of miR-380-3p ( t=4.96, P<0.01). The functional target gene of miR-380-3p may be UHRF1. The relative expression levels of UHRF1 mRNA in DU145 cells in the physcion group and control group were 0.23±0.06 and 1.04±0.15, respectively. Compared with the control group, the expression of UHRF1 gene in DU145 cells in the physcion group was decreased ( t=4.55, P<0.01). Conclusion:Physcion can inhibit the proliferation of prostate cancer DU145 cells and induce G 0/G 1 block in DU145 cells, which may be closely related to the regulation of miR-380-3p.

Avaliação de tecnologia assistiva sobre câncer de próstata e mama para deficientes visuais em países lusófonos / Evaluation of assistive technology about prostate and breast cancer for visually impaired persons in portuguese-speaking countries / Evaluación de tecnología de asistencia en cáncer de próstata y mama para personas con discapacidad visual en países de habla portuguesa

Objetivo: Avaliar a acessibilidade de tecnologia assistiva sobre câncer de próstata e de mama por deficientes visuais de dois países lusófonos. Métodos: Estudo metodológico de avaliação de tecnologia assistiva em saúde. Dados coletados com instrumento validado, constituído por 17 itens distribuídos nos atributos objetivos, acesso, clareza, estruturação e apresentação, relevância e eficácia e interatividade. Na análise, aplicaram-se Teste Qui-quadrado de Pearson, Teste Exato de Fisher ou Razão de Verossimilhança de acordo com os pressupostos dos testes. Os aspectos éticos foram respeitados. Resultados: A amostra foi de 62 participantes. As variáveis que tiveram diferenças estatísticas significantes foram escolaridade (p=0,006), tipos de deficiência (p=0,010) e desenvolvimento da deficiência (p= 0,005). Todas os atributos e itens obtiveram boas avaliações com alguns tópicos que não houve diferença estatística em ambos os países. Conclusão: As tecnologias assistivas sobre câncer de mama e próstata foram bem avaliadas, independente do país, brasileiros e portugueses as consideraram adequadas. (AU)

Objective: To evaluate the accessibility of assistive technology about prostate and breast cancer by visually impaired persons in two Portuguese-speaking countries. Methods: Methodological study of an assess assistive health technology. Data were collected from a validated instrument, comprising of 17 items distributed in the attributes, objective, access, clarity, structure and presentation, relevance and effectiveness and interactivity. In the analysis, the Pearson's Chi-squared test and the Fisher's exact test or likelihood ratios were applied according to the assumptions of the tests. The ethical aspects involved in the research were respected. Results: The sample was of 62 participants. The variables that exhibited any statistical diferences ware: schooling (p = 0.006); types of disabilities (p = 0.010) and; disabilities development (p = 0.005). All attributes and items had good evaluations, with some topics that there was no statistical difference among the countries. Conclusion: Assistive technology about prostate and breast cancer were well evaluated, regardless of the country, were considered adequate by brazilians and portuguese. (AU)

Objetivo: Evaluar la accesibilidad de la tecnología de asistencia en el cáncer de próstata y mama por personas con daño visual de dos países de habla portuguesa. Métodos: Estudio metodológico para evaluar la tecnología asistencial sanitaria. Datos recolectados con un instrumento validado, compuesto por 17 ítems distribuidos en los atributos objetivos, acceso, claridad, estructuración y presentación, relevancia y efectividad e interactividad. En el análisis se aplicó la prueba de chi-cuadrado de Pearson, la prueba exacta de Fisher o razón de verosimilitud según los supuestos de las pruebas. Se respetaron los aspectos éticos. Resultados: La muestra estuvo formada por 62 participantes. Las variables que presentaron diferencias estadísticamente significativas fueron educación (p = 0,006), tipos de discapacidad (p = 0,010) y desarrollo de la discapacidad (p = 0,005). Todos los atributos e ítems obtuvieron buenas evaluaciones con algunos temas que no hubo diferencia estadística en ambos países. Conclusion: Las tecnologías de asistencia en cáncer de mama y próstata fueron bien evaluadas, independientemente del país, brasileños y portugueses las consideraron apropiadas. (AU)

Prevenção ao câncer de próstata, masculinidade e cuidado: articulações possíveis a partir de revisão bibliográfica / Prevention of prostate cancer, masculinity and care: possible articulations from bibliographic review

O câncer de próstata constitui-se um importante agravo da saúde masculina, como apontam os dados epidemiológicos, sendo a experiência do diagnóstico e adoecimento transpassada por diferentes aspectos simbólicos relacionadas à masculinidade, sobretudo, não há evidências que justifiquem a organização de estratégias de rastreamento populacional. Esta revisão bibliográfica analisou produções de caráter qualitativo acerca dessa temática e suas articulações com a discussão sobre a masculinidade e o cuidado à saúde. Foram identificados 12 artigos, obtidos no SCielo e Medline, posteriormente selecionados e submetidos à análise temática. As abordagens desse tema nas produções identificadas foram organizadas em quatro categorias temáticas, a saber: (i) o câncer de próstata enquanto questão sexual; (ii) exames que tocam os homens; (iii) o teste do PSA em questão; e (iv) como enfrentar o rastreamento. Percebe-se que a discussão é traçada de modo deslocado dos sujeitos a que diz respeito e os aspectos de gênero que implicam nesse debate ainda são pouco evidenciados, de maneira que ainda carecem de maior aprofundamento crítico sob a perspectiva da masculinidade e cuidado à saúde.

Prostate cancer constitutes an important aggravation of male health, as shown by epidemiological data, with the experience of diagnosis and illness passing through different symbolic aspects related to masculinity, and, above all, there is no evidence to justify the organization of population screening strategies. This bibliographic review analyzed productions of a qualitative character about this theme and its articulations with the discussion about masculinity and health care. Twelve articles were identified, obtained from SCielo and Medline, later selected and submitted to thematic analysis. The approach to this theme in the identified productions was organized into four thematic categories, namely: (i) prostate cancer as a sexual issue, (ii) tests that touch men, (iii) the PSA test in question and (iv) how to face the screening. It is noticed that the discussion is drawn in a dislocated way from the subjects to which it concerns and the gender aspects that imply in this debate are still little evidenced, in such a way that they still need further critical deepening from the perspective of masculinity and health care.

Health-related quality of life and therapeutic adherence in breast and prostate cancer / Calidad de vida relacionada a la salud y adherencia terapéutica en los cánceres de mama y de próstata / Qualidade de vida relacionada à saúde e adesão terapêutica nos cânceres de mama e próstata

ABSTRACT Objective to correlate health-related quality of life and adherence to treatment of patients with breast and prostate cancer. Method an exploratory, descriptive and cross-sectional study, with a quantitative approach, conducted with 305 patients with breast and prostate cancer, in a state oncology hospital in Paraíba, Brazil, between June and November 2019. For data collection, a semi-structured instrument was used to obtain data regarding the sociodemographic and clinical profile, from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire "core" 30 items, from the specific module Quality of Life Questionnaire-Breast Cancer, and from the Adherence Determinants Questionnaire. Data analysis was performed using descriptive and inferential statistics. Results the correlation between health-related quality of life and adherence of patients with prostate cancer showed statistical significance (p≤0.05) between the Global health Scale and the Functional Scale, Intentions domain; emotional function and intentions; insomnia and subjective norms; financial difficulty and subjective norms. In women, there was statistical significance (p≤0.05) between role performance and subjective norms; fatigue and intentions; financial difficulty and total adherence; sexual desire, sexual satisfaction and perceived support/severity; breast symptoms and intentions. Conclusion health-related quality of life directly impacts on treatment adherence of patients with breast and prostate cancer.

RESUMEN Objetivo correlacionar la calidad de vida relacionada con la salud y la adherencia al tratamiento de pacientes con cáncer de mama y de próstata. Método estudio exploratorio, descriptivo y transversal, con enfoque cuantitativo, realizado con 305 pacientes con cáncer de mama y de próstata, en un hospital oncológico estatal de Paraíba, Brasil, entre junio y noviembre de 2019. En la recolección de datos, se utilizó un instrumento estructurado para la obtención de datos sobre el perfil sociodemográfico y clínico, el cuestionario del European Organization for Research and Treatment of Cancer Quality of Life Questionnaire "core" 30 itens, del módulo específico Quality of Life Questionnaire-Breast Cancer, y el Cuestionario de Determinantes de Adhesión. El análisis de datos se realizó por medio de estadística descriptiva e inferencial. Resultados la correlación entre la calidad de vida relacionada con la salud y la adherencia de los pacientes con cáncer de próstata mostró significancia estadística (p≤0.05) entre la Escala de Salud Global y la Escala Funcional, dominio Intenciones; función e intenciones emocionales; insomnio y normas subjetivas; dificultad financiera y normas subjetivas. En las mujeres, hubo significación estadística (p≤0.05) entre el desempeño de roles y las normas subjetivas; fatiga e intenciones; dificultad financiera y adhesión total; deseo sexual, satisfacción sexual y apoyo / severidad percibidos; síntomas de la mama e intenciones. Conclusión la calidad de vida relacionada con la salud tiene un impacto directo en la adherencia al tratamiento en pacientes con cáncer de mama y próstata.

RESUMO Objetivo correlacionar a qualidade de vida relacionada à saúde e a adesão ao tratamento de pacientes com câncer de mama e próstata. Método estudo exploratório, descritivo e transversal, com abordagem quantitativa, realizado com 305 pacientes com câncer de mama e de próstata, em hospital oncológico de referência estadual, na Paraíba, Brasil, entre junho e novembro de 2019. Para coleta de dados, utilizou-se de instrumento semiestruturado para obtenção de dados referentes ao perfil sociodemográfico e clínico, do questionário European Organization for Research and Treatment of Cancer Quality of Life Questionnaire "core" 30 itens, do módulo específico Quality of Life Questionnaire-Breast Cancer e Questionário de Determinantes de Adesão. A análise dos dados foi realizada por meio da estatística descritiva e inferencial. Resultados a correlação entre a qualidade de vida relacionada à saúde e a adesão de pacientes com câncer de próstata mostrou significância estatística (p≤0,05) entre a Escala de Saúde Global e a Escala Funcional, domínio Intenções; função emocional e intenções; insônia e normas subjetivas; dificuldade financeira e normas subjetivas. Nas mulheres, houve significância estatística (p≤0,05) entre desempenho de papéis e normas subjetivas; fadiga e intenções; dificuldade financeira e adesão total; desejo sexual, satisfação sexual e apoio/severidade percebida; sintomas da mama e intenções. Conclusão a qualidade de vida relacionada à saúde impacta diretamente a adesão ao tratamento de pacientes com câncer de mama e de próstata.

Differences in the diagnosis of prostate cancer by image fusion targeted biopsy, systematic biopsy and combined biopsy / 中华泌尿外科杂志

Objective:To explore the detection rate of prostate cancer and clinically significant prostate cancer (CsPCa) in three puncture methods: targeted biopsy fusion with MRI and ultrasound imaging, system puncture, and combined puncture.Methods:The clinical data of 164 patients who underwent both targeted biopsy and systematic biopsy in Zhejiang Provincial People's Hospital from April 2019 to April 2020 were retrospectively analyzed. The median age was 67(33-90)years. Preoperative serum tPSA was 8.97(0.64-95.63)ng/ml and fPSA was 1.31(0.29-9.25)ng/ml. There were 96 patients result in tPSA<10 ng/ml, 65 and 3 patients result in 10≤tPSA<50 ng/ml and tPSA≥50 ng/ml. The prostate volume was 34.9(11.6-152.0) cm 3. According to result of PI-RADS score, there were 42 patients got 3 points and 66, 56 patients got 4 and 5 points respectively in PI-RADS score of suspicious nodules. First, a targeted puncture (targeted biopsy) was performed on the suspected lesions by fusion imaging of magnetic resonance and ultrasound. Then 12-needle systematic prostate biopsy was performed under the guidance of ultrasound. Those two methods performed together was called combined biopsy. This study compared the detection rates of prostate cancer and CsPCa among the three popular methods in all cases, different PI-RADS cases, and different tPSA cases. Results:In this study, patients was detected as positive result in 126 of 164 patients. The detection rates of prostate cancer in targeted biopsy and systematic biopsy were 66.46%(109/164) and 64.02%(105/164), respectively, the result reveals no statistical significance ( P=0.64). In contrast, the positive rate of combined biopsy [76.83%(126/164)] was higher than targeted biopsy ( P=0.04) and systematic biopsy ( P=0.01), and the difference was statistically significant. In the detection rate of CsPCa, the positive detection rates of targeted biopsy group, systematic biopsy group and combined biopsy group were 50.61%(83/164), 45.12%(90/164) and 54.88% (126/164), respectively. Moreover, there was no significant statistical significance among the three groups ( P>0.05). Group comparison was analyzed according to PI-RADS score. In PI-RADS 4 group and PI-RADS 5 group, combined biopsy was[90.91%(60/66), 100.00%(56/56)] and systematic biopsy was [71.21%(47/66), 87.50%(49/56)] which reveals significant difference in prostate cancer detection rates ( P=0.00, P=0.01). In PI-RADS 4-5 groups, the detection rate of prostate cancer by targeted biopsy [86.89%(106/122)] was significantly higher than systematic biopsy [78.69%(96/122), P=0.01], but still lower than that by combined biopsy [95.08%(116/122), P=0.03]. The CsPCa detection rates of PI-RADS 3 group targeted biopsy, systematic biopsy and combined biopsy were 2.38%(1/42), 7.14%(3/42) and 7.14%(3/42), respectively. There were 59.09%(39/66), 46.97%(31/66) and 62.12%(41/66) in PI-RADS 4 groups, respectively; There were 78.57%(44/56), 71.43%(40/56) and 82.14%(46/66) in PI-RADS 5 groups, respectively, with no statistical significance ( P>0.05). However, in PI-RADS 4-5 groups, the CsPCa detection rate of combined biopsy [71.31%(87/122)] was higher than that of systematic biopsy [58.20%(71/122)], with statistical significance ( P=0.03). In the tPSA<10 ng/ml group, the prostate cancer detection rate of combined biopsy[72.92%(70/96)] was higher than that of systematic biopsy[59.38%(57/96)], and the difference was statistically significant ( P<0.05). There was no significant difference between the detection rate of targeted biopsy[61.43%(59/96)]and combined biopsy ( P=0.09). In the group of 10ng/ml≤tPSA<50ng/ml, the prostate cancer detection rates of targeted biopsy, systematic biopsy and combined biopsy were 72.31%(47/65), 69.23%(45/65) and 81.54%(53/65), respectively, and there was no statistical significance ( P>0.05). In tPSA≥50 ng/ml group, the prostate cancer detection rate of the three biopsy methods was 100.00% (3/3), and there was no statistical significance ( P>0.05). Conclusion:For patients with highly suspected prostate cancer on multiparameter MRI(PI-RADS 4-5) or tPSA<10 ng/ml, combined biopsy was an appropriate method to diagnose the prostate cancer.

The investigation of correlation between desmoplakin gene variant rs28763961 and prostate cancer in Northern Chinese / 中华老年医学杂志

Objective:To identify a novel desmoplakin(DSP)gene variants which associated with the risk of prostate cancer in Northern Chinese.Methods:Analyzing RNA-Seq data of tumor-normal pairs from 10 Northern Chinese cases with prostate cancer, 26 candidate single-nucleotide variants(SNVs)in tumor mRNA with potential biological significance were screened.The genotyping and association analysis of these variants were performed in the peripheral blood genomic DNA from 245 Northern Chinese individuals with prostate cancer and 100 matched controls by using Sequenom MassArray System.Results:We identified that two previously unrecognized SNVs CHST12 rs12536223 C>T( P=0.033, OR=2.730, 95% CI: 1.046-7.097)and DSP rs28763961 A>T( P=0.030, OR=0.55, 95% CI: 0.315-0.948)were associated with prostate cancer.Carriers of rs28763961T allele versus carriers of rs28763961A allele showed a higher DSP expression in tumor tissue( P=0.036)and lower total prostate-specific antigen(PSA)level( P=0.007)in peripheral blood. Conclusions:rs12536223 and rs28763961 are associated with prostate cancer in Northern Chinese.The carrier status of rs28763961T allele decreases the risk of prostate cancer.